Clinical Trial Update: A Pilot Study for the Treatment of Iris Neovascularization With Macugen [Phase 1]

View source ↗

Summary

Phase 1 pilot study evaluating pegaptanib (Macugen) for iris neovascularization related to diabetic retinopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Retinopathy
• Iris Neovascularization

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: Hermann Eye Center | Conditions: Iris Neovascularization, Diabetic Retinopathy | Phase 1 | Status: COMPLETED